Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Heart Fail Rev. 2020 May;25(3):481-485. doi: 10.1007/s10741-020-09919-x.
Heart transplantation (HTx) for patients with "giant cell myocarditis" (GCM) or "cardiac sarcoidosis" (CS) is still controversial. However, no single center has accumulated enough experience to investigate post-HTx outcome. The primary aim of this systematic review is to identify, appraise, and synthesize existing literature investigating whether patients who have undergone HTx because of GCM or CS have worse outcomes as compared with patients transplanted because of other etiologies. A systematic and comprehensive search will be performed using PubMed, Scopus, Web of Science, EMBASE, and Google Scholar, for studies published up to December 2019. Observational and interventional population-based studies will be eligible for inclusion. The quality of observational studies will be assessed using the Newcastle-Ottawa scale, while the interventional studies will be assessed using the Cochrane Effective Practice Organization of Care tool. The collected evidence will be narratively synthesized; in addition, we will perform a meta-analysis to pool estimates from studies considered to be homogenous. Reporting of the systematic review and meta-analysis will be in accordance with the Meta-analysis of Observational Studies in Epidemiology Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. To our knowledge, this will be the first synthesis of outcomes, including survival, acute cellular rejection, and disease recurrence, in patients with either GCM or CS treated with HTx. Reviewing the suitability of HTx in this population and highlighting areas for further research will benefit both patients and healthcare providers. Trial registration: CRD42019140574.
心脏移植(HTx)治疗“巨细胞心肌炎”(GCM)或“心脏结节病”(CS)患者仍存在争议。然而,没有一个中心积累了足够的经验来研究 HTx 后的结果。本系统评价的主要目的是确定、评估和综合现有文献,以调查因 GCM 或 CS 而接受 HTx 的患者与因其他病因接受 HTx 的患者相比,其结局是否更差。将使用 PubMed、Scopus、Web of Science、EMBASE 和 Google Scholar 进行系统和全面的搜索,以检索截至 2019 年 12 月发表的研究。将纳入观察性和干预性基于人群的研究。将使用纽卡斯尔-渥太华量表评估观察性研究的质量,而将使用 Cochrane 有效实践组织护理工具评估干预性研究的质量。将对收集到的证据进行叙述性综合;此外,我们还将进行荟萃分析,以合并被认为同质的研究的估计值。系统评价和荟萃分析的报告将符合观察性研究的荟萃分析流行病学优先报告项目的系统评价和荟萃分析指南。据我们所知,这将是首次综合 GCM 或 CS 患者接受 HTx 治疗后的生存、急性细胞排斥和疾病复发等结局的研究。评估该人群中 HTx 的适宜性并突出进一步研究的领域将使患者和医疗保健提供者受益。试验注册:CRD42019140574。